Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin dosing regimens in high cardiovascular-risk essential thrombocythemia
2016-002885-30Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aspirin in thrombocythemia (3 arms), sponsored by Policlinico Gemelli. Primary endpoint: Serum thromboxane B2 level. Started Nov 2020; status: completed.
02
Drugs
aspirin
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2016-002885-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002885-30.